Navigation Links
DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Date:5/5/2011

ely 300 patients, in the third quarter of 2011 with top-line data anticipated in the fourth quarter of 2011.  Based on a pooled and blinded analysis of the variability of data within BESST, we do not plan to increase the size of the study.

In February 2011, we announced results from a shoulder surgery Phase II study conducted in Europe by Nycomed.
At that time, we and Nycomed amended our agreement such that, for an interim period, DURECT will have full control and financial responsibility for non-clinical and CMC activities which had been previously jointly controlled and funded by DURECT and Nycomed.  If Nycomed elects to continue European development of POSIDUR after evaluation of BESST data, under the terms of the amendment, DURECT and Nycomed would resume joint control and financial responsibility of the non-clinical and CMC activities for the E.U. and the U.S.

POSIDUR is our post-operative pain relief depot that utilizes our patented SABER technology to deliver bupivacaine to provide up to three days of pain relief after surgery. POSIDUR is licensed to Hospira for commercialization in the U.S. and Canada, and to Nycomed for commercialization in Europe and other defined countries. We have retained commercialization rights in Japan and all other countries not subject to the Nycomed and Hospira licenses.

  • ELADUR (TRANSDUR®-Bupivacaine).  Pfizer completed its acquisition of King in February 2011 and as a result has assumed the development and commercialization rights and obligations to ELADUR.  In April 2011, we announced top-line results from a Phase II clinical trial conducted by King for the treatment of chronic low back pain.  The primary efficacy endpoint for the trial was not met.  Complete data analysis is on-going.  We and Pfizer are continuing to analyze these data and will work together to determine next steps for ELADUR.

  • ELADUR is our proprietary transdermal patc
    '/>"/>

    SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
    2. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    3. DURECT Corporation Announces Third Quarter 2008 Financial Results
    4. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    5. Techne Corporation Declares Dividend
    6. Techne Corporation Announces Acquisition
    7. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
    8. Vestaron Corporation Announces New Leadership
    9. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
    10. Every Day is Earth Day for Yulex Corporation
    11. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
    (Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
    (Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
    Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
    ... Pa., Feb. 23 Endo Pharmaceuticals (Nasdaq: ENDP ... by its wholly owned subsidiary, BTB Purchaser Inc., for all ... Inc. (Nasdaq: IDEV ). American Stock Transfer & ... Endo that, as of 5:00 p.m., New York City time, ...
    ... Calif., Feb. 23 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... results of the company,s SmartChip Real-Time PCR,System ... 16th,International Molecular Medicine Tri-Conference. The data ...
    ... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced that Dr. ... as of February 18, 2009. As a result of ... nine members.Dr. Dhingra has been active in oncology clinical ...
    Cached Biology Technology:Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 2Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 3Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 2Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 2Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 4Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 5
    (Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
    (Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
    (Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
    Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
    ... Researchers at the Buck Institute for Age Research ... to treat rodents afflicted with Parkinson,s Disease (PD). ... same group had previously developed, can be used to ... disease and paves the way for the use of ...
    ... AUGUSTA, Ga. Children at risk for diabetes before they ... bones, Medical College of Georgia researchers report. A study ... exercise found that the 30 percent with signs of poor ... measure of bone strength, said Dr. Norman Pollock, bone biologist ...
    ... that RNA plays a major role in cell biology, ranging ... as an important tool in functional genomics. Now WIREs RNA, ... providing RNA experts and researchers not only with a title ... to generate new insights and applications. "In the 10 ...
    Cached Biology News:Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2Diabetes risk in children increases risk for weak bones 2
    Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
    ... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
    ... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
    ... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
    Biology Products: